Delhi-based pain relief startup Wholeleaf is preparing to raise fresh funds as it continues to expand its presence in India’s growing alternative healthcare market. The company, which offers CBD-based products for pain management and wellness, is reportedly in advanced talks to raise around ₹7.5 crore from institutional investors.
The upcoming investment comes at a time when Wholeleaf is seeing strong growth in revenue, customer adoption, and retail distribution. The startup has built its brand around natural, plant-based solutions designed to help people manage chronic pain, inflammation, migraines, anxiety, and sleep-related problems.
Founded in December 2020 by Shivraj Sharma and Abhimanyu Sharma, Wholeleaf was created with the aim of making effective and accessible pain management products available to Indian consumers.
The idea behind the company came from a personal experience. Sharma was inspired after seeing the positive effects of CBD oil on a family member undergoing cancer treatment. This experience led him to explore the potential of plant-based therapies and eventually launch Wholeleaf.
Focus on Research-Backed Pain Management
Wholeleaf combines Ayurvedic knowledge with modern scientific research to develop its products. The company uses CBD extracted from cannabis leaves, which are legally allowed for medicinal use in India under the current regulatory framework.
Its product range includes Orthodexil for arthritis and inflammation, Migroheal for migraines, BLISS Mints for stress and focus, Sleep Tincture for better sleep, Combat Tincture for severe pain, and topical products such as Glide+ Gel and Rescue Balm.
A key factor that sets Wholeleaf apart is its focus on scientific testing. The startup says it has conducted 13 clinical trials across its products. According to the company, a majority of participants in these trials reported noticeable pain relief and improvement in their daily lives.
The products are manufactured in licensed GMP-certified Ayush facilities and are used under medical supervision where required. This research-based approach has helped the company build trust among consumers looking for alternatives to traditional pain relief treatments.
So far, Wholeleaf has served more than 100,000 customers across India and continues to attract people dealing with chronic pain, sleep disorders, anxiety, and recovery-related issues.
Shark Tank India Boosted Growth
Wholeleaf gained nationwide attention after appearing on Shark Tank India Season 5 earlier this year. During the show, founder Shivraj Sharma sought ₹50 lakh in exchange for 2.1% equity in the company.
The founders highlighted the company’s clinical research, legal compliance, and business growth during their pitch. Their presentation impressed several sharks, leading to multiple discussions around investment.
The startup eventually secured a deal worth ₹1.5 crore from Aman Gupta, Namita Thapar, and Kanika Tekriwal in exchange for 7.5% equity. The investment not only brought capital but also increased awareness of the brand among consumers.
Before its Shark Tank appearance, Wholeleaf had already raised around ₹3.5 crore from angel investors and startup investment networks. With the proposed ₹7.5 crore funding round, the company is now looking to accelerate its expansion plans.
The founders continue to hold a majority stake in the business, showing their long-term commitment to the company’s growth.
Revenue Growth and Expansion Plans
Wholeleaf has recorded rapid growth over the past 18 months. The startup currently reports an annual recurring revenue (ARR) of around ₹18 crore, reflecting increasing demand for its products.
Although the company is still investing heavily in growth and marketing, it maintains healthy gross margins of around 75%. A large portion of its spending goes towards customer awareness and brand building.
The company follows an omnichannel strategy, selling products through both online and offline channels. Most of its revenue comes from online sales, especially through its direct-to-consumer website.
Offline sales are supported by retail partnerships, with Apollo Pharmacy playing a major role in the company’s retail business. Wholeleaf products are currently available in around 1,000 to 2,000 stores, mainly across the Delhi-NCR region.
With the fresh funding, the startup plans to significantly expand its retail network. It aims to increase its presence to 5,000–7,000 outlets by the end of 2026. The expansion will focus on major cities such as Bengaluru, Mumbai, Hyderabad, Kolkata, Chennai, Ahmedabad, and Goa.
Looking ahead, Wholeleaf plans to achieve an ARR of ₹25 crore, enter more hospital chains, and explore international markets such as the UK and Europe. The company is also considering expansion into new categories, including pet wellness and premium skincare, as it works towards becoming one of India’s leading ethical cannabis-based healthcare brands.